Navigation Links
New model suggests feared side effect of Alzheimer's drugs is unlikely
Date:6/17/2010

The first trial of a new model for testing Alzheimer's treatments has reassured researchers that a promising class of drugs does not exacerbate the disease if treatment is interrupted.

Scientists at Washington University School of Medicine in St. Louis and Merck & Co. Inc studied the effects of a class of drugs known as gamma secretase inhibitors. Researchers had worried that these drugs might cause a build-up of proteins linked to Alzheimer's disease and that this build-up could be unleashed in a surge when patients went off the medications. But the new study suggests that they do not.

"This is important because it eases some concerns that have been raised about this potentially useful class of medications," says senior author Randall Bateman, MD, a Washington University neurologist who treats patients at Barnes-Jewish Hospital.

The findings appeared recently in The Journal of Neuroscience.

Gamma secretase inhibitors block proteins involved in the creation of amyloid beta, the main ingredient of Alzheimer's plaques. Patients cannot continuously take these drugs because nonstop inhibition of the gamma secretase enzyme has harmful side effects. One study had revealed that when physicians temporarily halted used of the inhibitors in humans, amyloid beta levels in the blood surged. An animal study suggested cessation of treatment also led to an amyloid beta increase in the brain. Researchers have been watching for similar effects in current human clinical trials of gamma secretase inhibitors.

The new study used a technique for measuring production and clearance of amyloid beta developed by Bateman and his colleagues at Washington University. It was the first time stable-isotope-labeling kinetics (SILK) was used in primates.

In a preliminary assessment of normal amyloid beta production and clearance rates, scientists found that the amyloid beta turnover in the subjects, a group of rhesus macaques, was 10 percent per hour.

"This is much closer to the human turnover rate of 8 percent per hour than other animal models," says co-first author Kristin Wildsmith, PhD, a postdoctoral research scholar. "That means we can be more confident that preclinical testing of Alzheimer's treatments in this model will produce results that accurately predict what the effects will be in humans."

When scientists gave the animals gamma secretase inhibitors, SILK testing showed that the drugs reduced production of amyloid beta. When researchers stopped inhibitors, blood levels of amyloid beta increased above normal levels. But SILK showed there was no increase in amyloid beta levels in the central nervous system.

"It appears that blood testing may not be the best way to monitor amyloid beta levels in the central nervous system," says Bateman, who says that the source of amyloid beta in the blood is unclear.

Brain amyloid beta is a fragment of a larger protein regularly disassembled as a part of normal metabolism. Wildsmith showed that treatment with gamma secretase inhibitors shifts this disassembly from an amyloid-beta-producing path to an alternative pathway that precludes the production of amyloid beta.


'/>"/>

Contact: Michael C. Purdy
purdym@wustl.edu
314-286-0122
Washington University School of Medicine
Source:Eurekalert

Related medicine news :

1. University of Pennsylvania: Contrary to popular models, sugar is not burned by self-control tasks
2. Solid tumor modeling focus of workshops
3. PivotPoint Doubles Down on Business Process Modeling with Advanced BPMN 2 + UML 2 Training
4. NYU College of Dentistry, Penn State develop new model for investigating tobacco/oral cancer link
5. Jenny McCarthy - Actress, Activist, and Model - Dedicates bforacure's ‘breasts are beautiful' to Help Raise Money for Breast Cancer Charities
6. Same disease, different stem cell models
7. Wyatt Matas & Associates Releases White Paper on Future Home Healthcare Business Model
8. Super Fitness Bikini Model Mega-Mogul Jennifer Nicole Lee Goes Global, British TV Appearance, QVC London May 12th Sharing Top Fitness Products
9. Former USAA President and Leading, Industry Expert Launch Contact-Center Management Company Featuring Innovative Business Model
10. Second volume of groundbreaking Emerging Model Organisms series is released
11. Global Premiere: Jennifer Nicole Lee, Super Fitness Model & Mega Brand, Reveals Ab Circle Mini on HSN's World Launch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... ... April 28, 2016 , ... ... Surgery Education and Anzu®, developers of the AnzuMedical™ Knowledge Sharing and Collaboration ... Collaborative Residency Network. The platform is scheduled to launch in July 2016 and ...
(Date:4/28/2016)... , ... April 28, 2016 , ... ... has been named a Top Doc in Physical Medicine and Rehabilitation by Philadelphia ... Castle Connolly Medical, Ltd. by randomly surveying physicians and medical leadership across the ...
(Date:4/28/2016)... ... 2016 , ... Starting today, households across the United States ... Prescription Assistance Program. They are customized to reflect the specific health needs of ... ready-to-use, state-themed card and, in the near future, material that highlights savings on ...
(Date:4/28/2016)... ... , ... North Hollywood dentist , Dr. Hamid Reza, now offers emergency ... comes to dental accidents or critical dental problems. These issues can threaten a person's ... knocked-out teeth, chipped teeth, and many other issues can lead to emergency situations, and ...
(Date:4/28/2016)... California (PRWEB) , ... April 28, 2016 , ... For many, a diet is only ... crave it if it does not look good. In addition, an individual cannot deny the ... well. , The team, therefore, has worked to create a product range that could ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... LEXINGTON, Massachusetts , April 27, 2016 ... announces that Jeff Poulton , Chief Financial Officer, will ... in Boston, MA on Wednesday, May ... live audio webcast will be available on the Presentations and ... Subsequently, a replay of the webcast will be available on ...
(Date:4/27/2016)... 2016 At the Sachs CEO ... a Phase 2 clinical study of its lead drug ... cochlear implantation (CI) surgery. This large, placebo-controlled, double-blind, phase ... Germany and France . ... the time of surgery. "Despite advances in cochlear implant ...
(Date:4/26/2016)... 2016 Research and Markets has announced ... Analysis of the Biological Medicine Industry in China 2016" ... analyzes the financial assessment and credit risk of the ... The report provides readers with an in-depth understanding of ... should be aware of. It considers current and future ...
Breaking Medicine Technology: